PD-L1 Regulation and Gastric Cancer Immune Evasion: Antigen Presentation, Immunotherapy Resistance Mechanisms, and Emerging Directions

PD-L1 Regulation and Gastric Cancer Immune Evasion: Antigen Presentation, Immunotherapy Resistance Mechanisms, and Emerging Directions

Gastric cancer exhibits pronounced molecular heterogeneity. Its development and progression are shaped not only by genetic alterations within tumor cells themselves but also by the tumor immune microenvironment. A review by Wang et al. published in CA: A Cancer Journal for Clinicians notes that the combination of PD-1/PD-L1 inhibitors and chemotherapy has become an important advance in gastric cancer treatment, with greater benefits observed in certain patient populations, including those with PD-L1-positive tumors or high microsatellite instability (MSI-H). However, PD-L1 expression alone cannot explain differences in treatment outcomes among all patients. Whether a tumor can generate and present antigens, retain the ability to respond to interferons, and support effective immune-cell infiltration into the tumor microenvironment also affects treatment outcomes.

Therefore, understanding PD-L1 requires examining the full immune regulatory process: upstream signals regulate its expression, antigen presentation determines T-cell recognition, and immunosuppression and tumor cell adaptations drive immune evasion and treatment resistance.

01

How Is PD-L1 Expression Regulated? From Inflammatory Signals to Oncogenic Pathways

PD-L1 is encoded by the CD274 gene. Its expression is regulated by various factors, including inflammatory cytokines, oncogenic signaling, hypoxia, and protein homeostasis. These regulatory mechanisms can be grouped into three main categories:

(1) IFN-γ–JAK–STAT1–IRF1 pathway: Activated CD8⁺ T cells and NK cells release IFN-γ, which activates JAK/STAT1 signaling and induces IRF1 expression, thereby promoting PD-L1 transcription and establishing adaptive immune resistance.:

(2) Other signaling pathways: Pathways such as NF-κB, MAPK, PI3K–AKT–mTOR, STAT3, and HIF-1α can promote PD-L1 expression in different tumor contexts, enhancing the immunosuppressive capacity of tumors.:

(3) Post-transcriptional regulation: Processes such as mRNA stability, protein glycosylation, ubiquitination, and membrane-protein trafficking can also affect PD-L1 expression levels, stability, and localization on the cell surface.:

These findings show that PD-L1 expression is regulated at multiple levels. Changes in its expression are associated not only with intrinsic signaling in tumor cells but also closely with the inflammatory and immune status of the tumor microenvironment.

02

How Does PD-L1 Promote Tumor Immune Evasion?

When tumor cells or other cells in the tumor microenvironment express PD-L1, it can bind to PD-1 on the surface of T cells and inhibit activation signals associated with the T-cell receptor (TCR), reducing T-cell proliferation, cytokine secretion, and cytotoxic activity. Under prolonged antigen stimulation, this inhibition may also reinforce T-cell exhaustion, allowing tumors to maintain a sustained immunosuppressive advantage.

It is important to note that PD-L1 is not expressed exclusively by tumor cells. Tumor-associated macrophages, dendritic cells, and other immune or stromal cells may also express PD-L1. Therefore, the proportion of PD-L1-positive cells in a tissue sample, PD-L1 expression on tumor-cell membranes, and PD-L1 expression by immune cells are not equivalent measures. Results may also vary depending on the detection platform, antibody clone, scoring system, and sampling region.

03

Defective Antigen Presentation: Another Important Route of Immune Evasion in Gastric Cancer

The PD-L1 axis primarily regulates immunosuppressive signaling, whereas recognition of tumor cells by CD8⁺ T cells also depends on intact antigen presentation. After antigens inside tumor cells are processed, they must be presented on the cell surface by major histocompatibility complex class I molecules (MHC-I/HLA-I) to be recognized by CD8⁺ T cells.

B2M , which encodes β2-microglobulin, is an essential component for maintaining the stable expression of classical MHC-I molecules. When B2M is functionally lost, the assembly and stability of HLA-I complexes may be impaired, resulting in reduced MHC-I expression on the cell surface. This, in turn, weakens tumor-antigen presentation and reduces the efficiency with which CD8⁺ T cells recognize tumor cells.

In addition to B2M, abnormalities in HLA genes and impaired TAP1/TAP2 function may also cause defects in antigen processing and presentation. Furthermore, IFN-γ–JAK–STAT1 signaling contributes to the regulation of PD-L1 expression and promotes the expression of MHC-I and related antigen-processing molecules. Dysfunction in this pathway may further aggravate tumor immune evasion.

04

From Immune Evasion to Treatment Resistance: Which Processes Should Be Examined Together?

Tumor immune evasion is the process by which tumor cells reduce the immune system's ability to recognize and eliminate them by altering immune-regulatory signals, weakening antigen recognition, and remodeling the tumor microenvironment. During immunotherapy, these mechanisms may not only result in primary resistance but may also gradually give rise to acquired resistance under sustained treatment pressure.

In light of the mechanisms regulating PD-L1 and antigen presentation, tumor immune evasion and treatment resistance mainly involve the following aspects:

(1) Sustained high PD-L1 expression: Binding of PD-1 to PD-L1 inhibits T-cell activation and cytotoxic function, weakening the antitumor immune response.

(2) Defective antigen presentation: B2M loss, abnormal HLA-I expression, and impairment of the TAP pathway may reduce the ability of CD8⁺ T cells to recognize tumor cells.

(3) Aberrant IFN-γ signaling: Dysfunction of molecules such as JAK1/JAK2 and STAT1 may weaken immune responses and antigen-presentation capacity in tumor cells.

(4) An immunosuppressive microenvironment: Regulatory T cells, tumor-associated macrophages, and myeloid-derived suppressor cells can inhibit effector T-cell function through various mechanisms, thereby promoting tumor immune evasion.

(5) Tumor heterogeneity and immune editing: Different tumor-cell subpopulations vary in their expression of antigens and immune-related molecules. Treatment pressure may promote the enrichment of immune-evasive subpopulations, leading to acquired resistance.

Tumor immune evasion and treatment resistance result from the combined effects of multiple mechanisms. In addition to PD-L1 expression, studies should consider B2M/HLA-I status, IFN-γ signaling, and the tumor immune microenvironment to gain a more comprehensive understanding of differences in responses to immunotherapy.

05

Emerging Research Directions: Moving Beyond Individual Immune Checkpoints Toward a Multidimensional Mechanistic Analysis

As research into tumor immunity advances, PD-L1 is no longer viewed merely as an isolated immune-checkpoint marker. Instead, it is part of an interconnected regulatory network involving antigen processing, antigen presentation, and immune-cell function. Future studies may focus on the following directions:

(1) Coordinated Regulation of PD-L1 and Antigen Presentation
Further investigate how IFN-γ–JAK–STAT1 signaling simultaneously affects CD274 expression and MHC-I antigen presentation, and clarify the roles and interactions of different molecular nodes in the process of immune evasion.

(2) Development and Reversibility of Antigen-Presentation Defects
Focusing on key molecules such as B2M, HLA-I, and TAP, investigate how genetic alterations, epigenetic regulation, and factors in the tumor microenvironment affect antigen-presentation capacity, and explore whether certain functional defects can be reversed.

(3) Using Gene-Edited Models to Study Mechanisms of Immune Evasion
Gene-knockout cell models enable researchers to investigate how the loss of specific molecules affects related signaling pathways and cellular functions. For example, the CD274-knockout HCT116 cell line developed by EDITGENE(Cat. No. EDC07704)  can be used in studies related to PD-L1 loss of function. The B2M-knockout HEK293T cell line (Cat. No. EDC07693)  can be used to investigate the mechanisms underlying B2M loss and changes in cell-surface MHC-I expression.Together with the respective parental controls and appropriate functional assays, these models can help further dissect two key processes: immune regulation and antigen presentation. It should be noted that neither of these ready-to-use cell lines is a gastric cancer model. If the research question specifically concerns gastric cancer, a corresponding model should be customized based on the relevant gastric cancer cell background.

(4) Establishing Research Systems That Better Recapitulate the Tumor Immune Microenvironment
Future studies may combine tumor organoids, co-cultures of tumor cells and immune cells, patient-derived samples, and appropriate in vivo models to comprehensively assess the relationships among PD-L1 expression, antigen-presentation capacity, and immune-cell function, thereby enhancing the clinical relevance of basic mechanistic research.

06

Conclusion

PD-L1 is an important node in the tumor immune-regulatory network. However, the success of immunotherapy depends not only on whether immunosuppression is relieved but also on whether tumor cells can still be recognized by the immune system. Integrating CD274 expression regulation, B2M-dependent MHC-I antigen presentation, IFN-γ signaling, and the tumor microenvironment into a unified research framework can help build a more systematic understanding of immune evasion and treatment resistance. For researchers, selecting well-validated gene-edited cell models that align with the scientific question is an important starting point for dissecting these complex mechanisms.

Edgene provides gene-edited cell models and related research tools, including gene-knockout cell model construction and CRISPR library screening services to support research on immune-checkpoint regulation, antigen presentation, and tumor immunity:

(1) Gene-Knockout Cell Models : Customized knockout models can be developed based on the target gene, cell background, and experimental requirements. Before starting a project, it is recommended to clarify the cell source, target site, editing strategy, clone selection, and validation requirements.

(2) CRISPR Library Screening : A suitable screening library can be selected based on the research focus for candidate-gene discovery, pathway screening, and functional studies. The specific library type, coverage, and conditions of use are subject to the product documentation.

For further information about product specifications, quality-control data, applicable cell backgrounds, or customization options, please contact Edgene. Model selection can then be confirmed in line with your specific research objectives.

References

[1] Wang F, Wang ZX, Zhang YJ, He Y, Ji JF, Li YF, Qu XJ, Ba Y, Yuan SQ, Xu RH. Advances in therapeutic approaches to gastric cancer. CA Cancer J Clin. 2026 Sep-Oct;76(5):e70103. doi: 10.3322/caac.70103. PMID: 42751916; PMCID: PMC13584074.

Tag


Leave a Reply

Your email address will not be published.Required Fields are marked
Contact Us
*
*
*
How did you hear about us: